PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) on Monday announced new real-world data from the IMPACT-TD Registry showing a significant gap in diagnosing tardive dyskinesia in patients with underlying mood disorders.
The data showed that 85% of adults aged 18 to 29 with mood disorders living with tardive dyskinesia experienced moderate to severe impact from the condition, while only 23% had received a formal diagnosis.
The analysis also found that patients waited an average of more than 3.5 years to receive a formal diagnosis after involuntary movements were first recognized.
Tardive dyskinesia is a chronic movement disorder associated with certain mental health treatments and is characterized by uncontrollable and repetitive body movements.
The findings were presented at the American Psychiatric Association Annual Meeting being held May 16-20 in San Francisco.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
